IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):324-326. doi: 10.1136/jnnp-2019-321977. Epub 2019 Nov 22.

Authors

Shahar Shelly^{1

2}, John R Mills¹, Jennifer M Martinez-Thompson², Matt M Rofforth¹, Sean J Pittock^{1

2}, Jay Mandrekar³, James Douglas Triplett², Michelle Mauermann², Divyanshu Dubey^{1

2}, C J Klein^{4

2}

Affiliations

¹ Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
² Neurology, Mayo Clinic, Rochester, Minnesota, USA.
³ Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA [email protected].

PMID: 31757814
DOI: 10.1136/jnnp-2019-321977

No abstract available

Keywords: CIDP; MADSAM; MGUS; MMN; gangliosides.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cohort Studies
Humans
Immunoglobulin M*
Motor Neuron Disease / complications*
Motor Neuron Disease / therapy
Paraproteinemias / epidemiology*
Paraproteinemias / therapy
Polyradiculoneuropathy / complications*
Polyradiculoneuropathy / therapy
Treatment Outcome

Substances

Immunoglobulin M